Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies

Chimeric antigen receptor T (CAR T) cell therapy is a new treatment paradigm that has revolutionized the treatment of CD19-positive B cell malignancies and BCMA-positive plasma cell malignancies. The response rates are highly impressive in comparison to historical cohorts, but the responses are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Atilla, Pinar Ataca, Atilla, Erden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136177/
https://www.ncbi.nlm.nih.gov/pubmed/35617812
http://dx.doi.org/10.1016/j.tranon.2022.101459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136177/
https://www.ncbi.nlm.nih.gov/pubmed/35617812
http://dx.doi.org/10.1016/j.tranon.2022.101459

Ejemplares similares